The Complete Guide to Halitosis and Dry Mouth: a domain map of aetiological classification, the role of saliva, and the evidence spectrum for management｜證據鏈

The Complete Guide to Halitosis and Dry Mouth: a domain map of aetiological classification, the role of saliva, and the evidence spectrum for management｜證據鏈

F-Units (fact ledger)

F1｜Saliva carries multiple functions: moistening and breaking down food, washing away particles, assisting swallowing, supplying minerals, protecting the mucosa, facilitating articulation and maintaining a balanced microbiota

• source #: #02 (official page)／#W9 (professional review)｜confidence: high｜basis: official_statement＋peer_reviewed (PMID 29878444)｜geo: universal｜period: NIDCR Last Reviewed 2024-10／J Oral Rehabil, 2018
• caveat: this is a functional description, not a quantified claim; it must not be used to infer the state of any individual reader's salivary function.

F2｜xerostomia (the subjective complaint of dry mouth) and hyposalivation (insufficient salivary secretion) are two concepts standing alongside each other, and do not necessarily occur together

• source #: #W21｜confidence: high｜basis: peer_reviewed (PMID 25653532)｜geo: universal｜period: Ther Clin Risk Manag, 2015
• caveat: this is a narrative review; this unit takes only its distinction of definitions and is not used for any conversion of prevalence figures.

F3｜The official position states plainly that dry mouth is not a normal part of ageing, and advises seeing a professional to establish the reason

• source #: #02｜confidence: high｜basis: official_statement (NIDCR)｜geo: universal｜period: Last Reviewed 2024-10
• caveat: this is an official patient-education position; it does not conflict with “the prevalence is higher in older populations” (F8), and neither of the two may be substituted for the other.

F4｜The formal classification of halitosis has three tiers: genuine／pseudo-halitosis／halitophobia; genuine is then divided into physiological and pathological; pathological is then divided into intra-oral and extra-oral

• source #: #W2 (classification)／#W3 (management on the psychological side)｜confidence: high｜basis: peer_reviewed (PMID 12090449／11908365)｜geo: universal｜period: Int Dent J, 2002／Compend Contin Educ Dent, 2000
• caveat: both papers are comparatively old (2000／2002) and represent a classification framework carried forward within the field; the two point in different directions on “whether pseudo-halitosis can be managed by a dentist” (#W2 says it can, #W3 says it cannot), and this article therefore cites nothing at that point of divergence, taking only the part on which the two agree (halitophobia requires referral to psychological professionals).

F5｜Intra-oral factors account for 80–90% of the aetiology of halitosis (the principal ones being tongue coating, periodontal disease and poor oral hygiene) and extra-oral factors for 10–20%; a separate topical review of the extra-oral type estimates that type at about 5–10%

• source #: #05 (80–90%／10–20%)／#W4 (5–10%)｜confidence: moderate｜basis: peer_reviewed (PMID 35212093／21386205)｜geo: universal｜period: Oral Dis, 2023／J Breath Res, 2010
• caveat: the two sets of percentages are calculated on different bases; they may not be compared with one another and no average may be taken; this article sets both out side by side and states plainly where the difference comes from. The two agree in direction (most of the aetiology is intra-oral).

F6｜The chemical basis of halitosis is the degradation of sulfur-containing amino acids by anaerobic bacteria to produce VSCs (hydrogen sulfide and methyl mercaptan being the representatives); tongue coating is considered the principal source of VSCs; the representative compound in blood-borne halitosis is dimethyl sulfide

• source #: #W4｜confidence: moderate｜basis: peer_reviewed (a review, PMID 21386205)｜geo: universal｜period: J Breath Res, 2010
• caveat: this is a narrative review; “the principal source” is that paper's judgement, not the conclusion of a meta-analysis.

F7｜Halitosis is positively correlated with periodontitis (organoleptic test OR 4.05, VSC readings OR 4.52), although the conclusions are limited by statistical heterogeneity

• source #: #06｜confidence: moderate｜basis: peer_reviewed (SR/MA, PMID 38801476)｜geo: universal｜period: Clin Oral Investig, 2024; 9 observational studies
• caveat: the included studies are of observational design, which can show association only and cannot support causal inference; the original states of itself that heterogeneity limits the certainty of its conclusions.

F8｜The reported prevalence figures for halitosis and dry mouth differ widely: halitosis 50–60% (has experienced)／30–50% (a review-level quotation)／8.9% (organoleptic measurement in a single healthy population); dry mouth 23% (quoted from a global meta-analysis)／20–30% (a long-term care review)／38% (a 2025 meta-analysis, I²=97%)

• source #: #04／#W17／#W18 (halitosis); #W1／#W10／#W12 (dry mouth)｜confidence: low (comparability across sources)｜basis: peer_reviewed (PMID 31825092／35127785／42492573／38530258／34698291／40889540)｜geo: universal｜period: 2019／2021／2026／2024／2021／2025
• caveat: the methods of measurement, the populations and the time windows of the six figures all differ; none of them may be compared with another and no average may be taken; the population of #W18 was 113 systemically and orally healthy orthodontic patients, not a sample of the general population; the heterogeneity of #W12 was I²=97%.

F9｜The reliability of judging one's own halitosis is low: the agreement between self-report and objective assessment was weak (κ=0.264); in the same study the agreement between a portable device and organoleptic assessment was significant and substantial

• source #: #W18｜confidence: low｜basis: peer_reviewed (cross-sectional study, PMID 42492573)｜geo: universal｜period: J Breath Res, 2026; n=113
• caveat: single centre, single population (orthodontic patients), cross-sectional design; it must not be extrapolated as the accuracy of self-judgement across the whole population, nor used as a basis for recommending any device.

F10｜The official classification of the causes of dry mouth has five classes: side effects of medication, disease, radiotherapy, chemotherapy and immunotherapy, and nerve damage

• source #: #02｜confidence: high｜basis: official_statement (NIDCR)｜geo: universal｜period: Last Reviewed 2024-10
• caveat: this is a classification framework and provides no relative proportion for the classes; this article makes no quantified ranking of the weight of each class.

F11｜Medication is the class of cause of dry mouth in which the evidence has accumulated most thickly: 56 chemical substances with a higher level of evidence and 50 with a moderate level have been compiled, spanning 9 of the 14 major ATC groups; before this, no evidence-based medication list existed

• source #: #15 (the list)／#14 (clinical action and limits)｜confidence: high (existence of the list)／moderate (epidemiology)｜basis: peer_reviewed (PMID 27853957／25994331)｜geo: universal｜period: Drugs R D, 2017／Clin Oral Investig, 2015
• caveat: the search cut-off was June 2013, and medicines marketed after that are not included; the original states of itself that the epidemiological data are limited and that most studies have small samples and heterogeneous methods. This unit constitutes no instruction to take or to stop any medication.

F12｜Polypharmacy is the principal risk factor for dry mouth; the more medications, the higher the anticholinergic burden; more than 3 oral medications a day is associated with dry mouth (OR 2.9, 95% CI 1.4–6.2)

• source #: #W10 (mechanism and risk factor)／#W1 (odds ratio)｜confidence: moderate｜basis: peer_reviewed (PMID 34698291／38530258)｜geo: universal｜period: Pharmacy, 2021／JAMA, 2024
• caveat: #W1 is association data quoted in a journal review and is observational evidence; no causal inference may be drawn from it, and it may not serve as a basis for adjusting medication.

F13｜Medication review and deprescribing are regarded as a key strategy, but no randomised controlled trial has yet demonstrated that they reduce the incidence of dry mouth

• source #: #W10｜confidence: high (statement of a gap)｜basis: peer_reviewed (a review, PMID 34698291)｜geo: universal｜period: Pharmacy, 2021
• caveat: “no RCT yet” is the wording as of 2021, and this round obtained no evidence of a relevant RCT since then, although the existence of one is not excluded; this unit is a record of a gap in the evidence, not a negation of the strategy.

F14｜The relationship between age and saliva has to be set out on three sides: the official position that dry mouth is not a normal part of ageing; the higher prevalence in older populations; and, physiologically, that age-related change is “frequently assumed” while the existing data are affected by collection method and by factors other than age

• source #: #02 (official position)／#10・#W10・#W12 (prevalence)／#W11 (physiology and methodological limits)｜confidence: moderate｜basis: official_statement＋peer_reviewed (PMID 39838537／34698291／40889540／30091142)｜geo: universal｜period: 2024-10／2025／2021／2025／2019
• caveat: the three sides do not conflict but are frequently conflated; #W11 marks explicitly the influencing factors other than age (health status, polypharmacy), so the higher prevalence in older people must not be attributed directly to ageing itself.

F15｜Sjögren's syndrome has formal international classification criteria, one item of which is an unstimulated whole saliva flow rate of ≤0.1 mL/minute; those criteria state that they apply to individuals with suggestive signs or symptoms and are positioned as criteria for enrolment in clinical trials

• source #: #W8｜confidence: high｜basis: clinical_guideline (ACR/EULAR consensus statement, PMID 27785888)｜geo: universal｜period: Arthritis Rheumatol, 2017
• caveat: classification criteria are not a diagnostic tool, and still less a self-check list; this article cites them for one purpose only, to show that dry mouth can be quantified objectively and that this quantification is a clinical procedure.

F16｜In adults, type 2 diabetes may lead to a rise in the caries index and to falls in salivary flow rate, pH and buffering capacity

• source #: #W20｜confidence: moderate｜basis: peer_reviewed (SR/MA, PMID 39216817)｜geo: universal｜period: J Dent, 2024; 39 studies qualitative／28 quantitative
• caveat: the included studies are of observational design and the original's wording is “may lead to”, which must not be rewritten as a certainty; the full discussion of the interface with systemic disease belongs to P19.

F17｜The downstream consequences of insufficient saliva have several strands of observational evidence: raised risk of tooth decay and fungal infection; a relative 11.5% increase in the risk of candidal infection; an association with dysphagia at OR 8.1; and 13 studies reporting a significant association with malnutrition in older people

• source #: #02・#W9 (direction of risk)／#W1 (11.5%)／#W22 (OR 8.1)／#W12 (nutrition)｜confidence: moderate｜basis: official_statement＋peer_reviewed (PMID 29878444／38530258／36207669／40889540)｜geo: universal｜period: 2024-10／2018／2024／2022／2025
• caveat: all of these are observational associations from which no causal inference may be drawn; the outcome in #W22 is swallowing impairment rather than dry mouth itself, dry mouth being one of the associated factors in that analysis.

F18｜The sources higher up the evidence hierarchy on halitosis interventions show low to very low certainty and could not determine the superiority of any intervention or concentration; that review excluded patients secondary to systemic disease and masking interventions, and most trials had short-term follow-up only

• source #: #04｜confidence: high (statement of evidence level)｜basis: peer_reviewed (Cochrane SR/MA, PMID 31825092)｜geo: universal｜period: Cochrane Database Syst Rev, 2019; 44 trials, 1809 people
• caveat: “the evidence is insufficient to judge superiority” is not the same as “the methods are ineffective”; the scope of its conclusions is confined to intra-oral halitosis. Search cut-off April 2019.

F19｜Tongue cleaning has quantified evidence in the short to medium term (effect sizes of 0.745／0.922 on VSCs and the tongue-coating index; all experiments showed a positive effect), but the data on the long-term effect on chronic halitosis are insufficient and there is not enough evidence to recommend a frequency, duration or manner of performing it

• source #: #08 (positive effect and the long-term gap)／#09 (effect sizes and the gap on operating parameters)｜confidence: moderate (short to medium term)／low (long term)｜basis: peer_reviewed (SR/MA, PMID 20961381／24165218)｜geo: universal｜period: Int J Dent Hyg, 2010／Nurs Res, 2013
• caveat: both papers are comparatively old and small in scale (#08 = 5 publications／7 experiments; #09 = 5 RCTs／7 experimental data sets, participants 188 male and 63 female); #04 (Cochrane) rated the dentist-reported organoleptic test outcome for “mechanical tongue cleaning versus no tongue cleaning” as very low-certainty evidence, that comparison having only 2 trials and 46 participants; the short- to medium-term evidence must not be escalated into a daily instruction on technique, and no tool or number of repetitions may be specified.

F20｜There is insufficient evidence of added value for alternative therapies in the treatment of halitosis; the risk of bias was high in all the included articles; and no ingredient showed a clearly consistent positive effect

• source #: #13｜confidence: moderate｜basis: peer_reviewed (SR, PMID 33227726)｜geo: universal｜period: J Breath Res, 2021; 26 papers
• caveat: a meta-analysis could not be performed because heterogeneity was too high; “insufficient evidence” is a gap in the evidence, not proof of ineffectiveness.

F21｜The three analyses of probiotics for halitosis point in inconsistent directions: not reaching significance (p=0.53)／possible short-term relief／significant reduction in VSCs; all three state limits on their own reliability

• source #: #W17／#W15／#W16｜confidence: low｜basis: peer_reviewed (SR/MA, PMID 35127785／36600415／41289613)｜geo: universal｜period: Front Nutr, 2021／BMJ Open, 2022／J Breath Res, 2025
• caveat: all three must be set out side by side and none of them chosen over the others; their inclusion criteria, division of follow-up time and outcome measures differ. Probiotic products fall within the category of foods or health foods in most regions, and this unit constitutes no claim of therapeutic effect for, and no recommendation of, any product.

F22｜The logic at the guideline layer for halitosis is “classify by cause, then match the treatment”, and a consensus framework has been established; the routes of management divide into three — masking the odour, reducing VOC/VSC concentrations, and mechanical and/or chemical management

• source #: #01 (consensus framework and classification strategy)／#W5 (the three routes)｜confidence: moderate｜basis: clinical_guideline＋peer_reviewed (PMID 41678945／25825113)｜geo: universal｜period: Int Dent J, 2026／J Contemp Dent Pract, 2014
• caveat: the abstract of #01 does not state the full name of the issuing association (describing it only as a consensus framework), so this article uses the wording “a clinical practice guideline published in an international dental journal” and invents no association name; nor does it cite any of its specific treatment parameters.

F23｜The spectrum of methods for measuring halitosis: organoleptic measurement is described as the procedure highest in practical feasibility; gas chromatography with a flame photometric detector is recorded as the gold standard and correlates highly with VSC concentration; and there are also sulfide monitoring, microbiological testing and chemical test strips

• source #: #W2 (organoleptic／GC)／#W5 (the list of methods)｜confidence: moderate｜basis: peer_reviewed (PMID 12090449／25825113)｜geo: universal｜period: 2002／2014
• caveat: both papers are comparatively old and instrument technology may have moved on since; this article takes only the classification of methods and makes no comparison or recommendation of any equipment's performance.

F24｜The ceiling of the evidence on managing dry mouth: of 48 studies only 3 were high-quality systematic reviews and more than 80% were rated of very low quality; there is limited evidence for topical therapies; substitutes and stimulants mostly have a short-term effect

• source #: #10｜confidence: high (statement of evidence quality)｜basis: peer_reviewed (umbrella review, PMID 39838537, PROSPERO CRD42022325854)｜geo: universal｜period: Gerodontology, 2025; searched to 2023-09
• caveat: an umbrella review appraises “the quality of the reviews” rather than “the effect of the interventions”; the evidence for acupuncture／amifostine／sialogogic medication is marked as of low quality.

F25｜Artificial saliva substitutes reduced dry mouth symptoms in every one of the 10 clinical trials in a qualitative synthesis, but should be selected according to individual needs, and the included studies covered a wide range of products with a high risk of bias

• source #: #11｜confidence: low｜basis: peer_reviewed (SR, PMID 30923424)｜geo: universal｜period: J Pharm Bioallied Sci, 2019
• caveat: a qualitative synthesis with no meta-analysis performed; this unit is a statement at the level of product category, involves no brand and constitutes no recommendation.

F26｜Of 72 clinical guidelines on dry mouth worldwide (42 countries, 6 continents) only 2 met the AGREE II standard for recommendation; dry mouth remains an under-recognised and under-managed symptom; but many care practices are shared worldwide

• source #: #12｜confidence: high｜basis: peer_reviewed (SR of guidelines, registered with PROSPERO before 2023, PMID 42051234)｜geo: universal｜period: Palliat Med, 2026
• caveat: the scope of that review is guidelines in the palliative care setting, and it must not be extrapolated directly as the state of guidelines in general dental practice; this article cites it in order to show the commonality and the quality gap at the institutional layer.

F27｜The cancer-treatment population has a dedicated clinical practice statement for dry mouth management, with pathways divided into stimulating residual secretion and artificial moistening; on the evidence side, two prescription sialogogues reduced symptoms and increased flow relative to placebo, although aspects of the effect size, duration of benefit and clinical meaningfulness remain unclear, and the evidence for other management approaches is insufficient to support them

• source #: #W6・#W7 (the statements)／#W13 (meta-analysis)／#W14 (non-pharmacological)｜confidence: moderate｜basis: clinical_guideline＋peer_reviewed (PMID 39048728／39048727／28249650／37946598)｜geo: universal｜period: Support Care Cancer, 2024／Oral Oncol, 2017／Oral Dis, 2024
• caveat: the population to which this applies is patients undergoing cancer treatment, and it must not be extrapolated to the general dry mouth population; the search cut-off for #W13 was July 2016. This unit constitutes no medication advice and no dose instruction, and the use of prescription medicines is decided by a physician throughout.

F28｜The diagnosis of dry mouth depends on a detailed history and a complete oral examination, including asking about medications; ideally objective and subjective measurement should be carried out together

• source #: #02 (official)／#W21 (review)／#W7 (assessment statement)｜confidence: high｜basis: official_statement＋clinical_guideline＋peer_reviewed (PMID 25653532／39048727)｜geo: universal｜period: 2024-10／2015／2024
• caveat: the setting of #W7 is the clinical assessment of cancer patients; this article takes its methodological principle of “objective and subjective in parallel” and cites none of its population-specific criteria.

Compliance note

• This article is health education and a compilation of medical developments. It is general oral-health education information, does not solicit medical business, does not constitute medical advertising, and does not constitute diagnostic or treatment advice.
• This article provides no amount, fee or coverage information, recommends no healthcare institution, clinician, brand or product, contains no identifiable individual case, and contains no third party's subjective commentary on a course of treatment.
• This article contains no instruction on taking, dosing, stopping or applying any medication. Citations involving prescription medicines present only the research conclusions of systematic reviews and their limits, described at the level of a class; the English in the footnotes is a verbatim quotation of the original literature, provided for verification and not as medicinal advertising. The use, substitution or discontinuation of any medicine must be decided by the prescribing physician throughout.
• Probiotics, artificial saliva substitutes and oral cleaning products fall within the category of foods, health foods or general goods in most regions; the relevant passages of this article are a compilation of results from the literature and claim no medical efficacy for them and constitute no product recommendation.
• This article compiles no symptom-grading table, no red-flag list and no self-assessment scale; symptom grading belongs to the scope of P13 and P15.
• All the data in this article are research results at population level. Actual treatment approaches and outcomes vary from person to person and must be assessed by a dentist before any decision.
• ⚠ Compliance reminder: section 2-2 and section 9-4 touch on the assessment of psychological state and on classes of prescription medicine; human review is recommended.
• This article is a draft. It has not passed the publication gate, the four language versions are not yet complete, and it is for internal review only.

Source list

Date of access / live verification: 2026-08-06 (all sources verified live on the same day via curl / PubMed E-utilities, HTTP 200, with verbatim spans passing programmatic comparison)

Pre-verified sources from the anchor file (`ida-pillars/anchors/P17-anchors.md`)

Statement in the opening section of the anchor file: under the owner's 2026-08-06 decision that this whole line is global, Taiwanese regulatory, health insurance and health bureau content is used as the basis of no medical or system claim in this article, and local systems are all handled by downstream links to the corresponding TW canonical card and P12. The official_statement tier of this article is taken from the internationally applicable patient-education pages of US federal health agencies (NIDCR／MedlinePlus), and is not the insurance or regulatory content of any single country.

WRITER-ADDED SOURCES (added for this article, with live evidence)

Reason for the additions: the anchor file covers four patient questions, but the scope of this domain article further includes (i) the physiological functions of saliva and the terminological distinction between xerostomia and hyposalivation, (ii) the formal three-tier classification of halitosis and the principles of management on the psychological side, (iii) the mechanism of the intra-oral／extra-oral boundary and a second source for the proportions, (iv) the spectrum of measurement methods, (v) the age, disease and polypharmacy aspects of dry mouth, (vi) the downstream consequences of insufficient saliva, (vii) the dedicated clinical practice statement for the cancer-treatment population, and (viii) the divergence in the direction of the probiotics evidence. All 22 sources below were verified live by curl on this machine (HTTP 200) and passed programmatic verbatim comparison, with no modification to the anchor file.